

# CITATION REPORT

List of articles citing

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

DOI: 10.1002/14651858.cd011381.pub2  
The Cochrane Library, 2015, , CD011381.

**Source:** <https://exaly.com/paper-pdf/60218338/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
108	Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. <b>2015</b> , 7, 157-67		19
107	The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. <b>2016</b> , 11, e0163296		20
106	Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. <b>2016</b> ,		
105	Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis. <b>2016</b> , 30, 909-29		19
104	Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	
103	Fingolimod for relapsing-remitting multiple sclerosis. <i>The Cochrane Library</i> , <b>2016</b> , 4, CD009371	5.2	33
102	Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. <b>2017</b> , 88, 677-684		15
101	Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. <b>2017</b> , 6, 91-102		49
100	Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. <b>2017</b> , 7, e013430		35
99	Approved drugs for multiple sclerosis: the challenge of choice. <b>2017</b> , 16, 252-253		7
98	? Daclizumab for MS. <b>2017</b> , 55, 18-21		0
97	Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. <b>2017</b> , 77, 885-910		16
96	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. <i>The Cochrane Library</i> , <b>2017</b> , 4, CD012200	5.2	8
95	Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System. <b>2017</b> , 198, 4607-4617		11
94	"Cure" for multiple sclerosis (MS)-Evolving views of therapy goals in patients on different stages of the disease: A pilot study in a cohort of Polish MS patients. <b>2017</b> , 7, e00701		2
93	A new graphical format to communicate treatment effects to patients-A web-based randomized controlled trial. <b>2017</b> , 20, 797-804		13
92	Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies. <b>2017</b> , 33, 579-593		18

91	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. <b>2017</b> , 7, e018612		3
90	Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	4
89	Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation. <b>2017</b> , 187, 383-398		12
88	Macrolides for treatment of <i>Haemophilus ducreyi</i> infection in sexually active adults. <i>The Cochrane Library</i> , <b>2017</b> , 12, CD012492	5.2	5
87	Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferon $\beta$ 1a. <b>2017</b> , 7, 47-60		4
86	Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DISCUTIR MS. <b>2017</b> , 11, 175-180		8
85	IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis. <b>2017</b> , 8, 1258		21
84	Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DISCUTIR MS). <b>2017</b> , 8, 65		29
83	Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. <b>2017</b> , 8, 430		15
82	Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011-2015. <b>2017</b> , 13, 2737-2745		7
81	Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data. <b>2018</b> , 2, 31-41		12
80	Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. <b>2018</b> , 265, 999-1009		16
79	Preapproval and postapproval evidence on drugs for multiple sclerosis. <b>2018</b> , 90, 964-973		11
78	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. <b>2018</b> , 89, 1050-1056		59
77	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. <b>2018</b> , 36, 161-173		16
76	Information provision for people with multiple sclerosis. <i>The Cochrane Library</i> , <b>2018</b> , 10, CD008757	5.2	20
75	A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis. <b>2018</b> , 10, 88-105		27
74	Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. <i>BMC Neurology</i> , <b>2018</b> , 18, 162	3.1	15

73	Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. <b>2018</b> , 9, 781	7
72	The Role of Prescribing Generic (Non-proprietary) Drugs in the Prevalence of Therapeutic Inertia in Multiple Sclerosis Care. <b>2018</b> , 9, 835	3
71	Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. <b>2018</b> , 24, 570-576	2
70	Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. <b>2018</b> , 4, 20552173187752361	
69	Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up. <b>2018</b> , 13, e0197759	20
68	Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. <b>2018</b> , 9, 522	2
67	Planning a future randomized clinical trial based on a network of relevant past trials. <b>2018</b> , 19, 365	21
66	Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis. <b>2018</b> , 32, 813-826	34
65	Cladribine tablets added to IFN- $\beta$ in active relapsing MS: The ONWARD study. <b>2018</b> , 5, e477	36
64	Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study. <b>2018</b> , 25, 276-281	6
63	Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. <b>2018</b> , 89, 1200-1207	28
62	Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. <b>2018</b> , 21, 968-976	3
61	Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care. <b>2019</b> , 4, 2381468319855642	5
60	Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis. <b>2019</b> , 266, 2867-2868	4
59	Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain. <b>2019</b> , 2, e197093	11
58	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <b>2019</b> , 93, 793-809	13
57	A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. <b>2019</b> , 4, 2381468319879134	1
56	Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. <i>The Cochrane Library</i> , <b>2019</b> , 1, CD010871	5.2 13

55	Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab. <b>2019</b> , 64, 2688-2689		3
54	Enduring Clinical Value of Copaxone <sup>®</sup> (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. <b>2019</b> , 2019, 7151685		7
53	Mobile phone text messaging for the prevention of sexually transmitted infections. <i>The Cochrane Library</i> , <b>2019</b> ,	5.2	0
52	Antibiotic therapy for adults with neurosyphilis. <i>The Cochrane Library</i> , <b>2019</b> , 5, CD011399	5.2	2
51	Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme. <b>2019</b> , 5, 2055217319893103		3
50	Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. <b>2019</b> , 22, 226-237		7
49	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. <b>2019</b> , 27, 364-369		16
48	Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 955-963	5	8
47	Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. <b>2020</b> , 267, 3489-3498		39
46	Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. <b>2020</b> , 38, 101498		6
45	Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. <b>2020</b> , 37, 225-235		10
44	Factors associated with therapeutic inertia among pharmacists caring for people with multiple sclerosis. <b>2019</b> , 39, 101887		2
43	Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. <b>2020</b> , 34, 65-92		10
42	The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis. <b>2020</b> , 86, 637-645		10
41	Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. <b>2020</b> , 15, e0238476		0
40	Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. <b>2020</b> , 19, 1069-1094		15
39	Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. <i>The Cochrane Library</i> , <b>2020</b> , 10, CD012859	5.2	14
38	Early clinical markers of aggressive multiple sclerosis. <b>2020</b> , 143, 1400-1413		13

37	Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis. <b>2020</b> , 10,		13
36	Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. <b>2020</b> , 9, 197-203		7
35	Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. <i>The Cochrane Library</i> , <b>2020</b> ,	5.2	1
34	Possible determinants of long-term adherence to physical activity in multiple sclerosis-theory-based development of a comprehensive questionnaire and results from a German survey study. <b>2021</b> , 43, 3175-3188		5
33	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. <b>2020</b> , 20, 771-782		3
32	Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community. <b>2020</b> , 27, 1250-1256		1
31	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. <b>2021</b> , 92, 189-194		4
30	The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis. <b>2021</b> , 861-862, 503278		1
29	Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1). <b>2021</b> , 11, e041720		2
28	Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)-Results of a Pilot Randomized Controlled Trial. <b>2021</b> , 12, 644533		0
27	The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis. <b>2021</b> , 11, 103-111		1
26	Secondary progressive multiple sclerosis: number of patients and public drug supply in Russia. <b>2021</b> , 38		
25	Structural and Functional Neuroimaging in Multiple Sclerosis: From Atrophy, Lesions to Global Network Disruption. <b>2018</b> , 171-213		1
24	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <b>2021</b> , 96, e783-e797		18
23	Beneficial effects of fingolimod in MS patients with high serum Sema4A levels. <b>2018</b> , 13, e0193986		8
22	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. <b>2017</b> , 21, 1-352		21
21	Mittel zur Behandlung der multiplen Sklerose. <b>2016</b> , 561-575		
20	How do immunomodulators and immunosuppressants compare in people with relapsing-remitting multiple sclerosis?.		

- 19 Mittel zur Behandlung der multiplen Sklerose. **2017**, 571-587
- 18 Mittel zur Behandlung der multiplen Sklerose. **2018**, 619-636
- 17 Planning a future randomized clinical trial based on a network of relevant past trials.
- 16 Pharmakologische Behandlung der multiplen Sklerose. **2019**, 799-816
- 15 Early clinical markers of aggressive multiple sclerosis. 1
- 14 Pharmakologische Behandlung der multiplen Sklerose. **2020**, 653-670 1
- 13 Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis. **2021**, 11, e051509
- 12 Reviewing the Unmet Needs of Patients with Multiple Sclerosis. **2015**, 8, 426-31 9
- 11 Pharmakologische Behandlung der multiplen Sklerose. **2021**, 561-578
- 10 Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.. **2021**, 12, 794075
- 9 Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets.. **2021**, 12, 815842 4
- 8 Multiple Sclerosis Relapses Following Cessation of Fingolimod.. *Clinical Drug Investigation*, **2022**, 42, 3553.2 1
- 7 The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life. *International Journal of MS Care*, **2021**, 2.3
- 6 Disease-modifying drugs for multiple sclerosis and subsequent health service use.. *Multiple Sclerosis Journal*, **2021**, 13524585211063403 5 1
- 5 Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. *BMC Neurology*, **2022**, 22, 3.1
- 4 Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis. jnp-2022-329223
- 3 Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. **2022**, 2022, 0
- 2 Multiple Sklerose. **2022**, 497-517 0

1 Future Path and Perspectives of Immunomodulators. **2023**, 399-412

o